Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist)
Journal of Lipid and Atherosclerosis
; : 32-41, 2018.
Article
em Ko
| WPRIM
| ID: wpr-714786
Biblioteca responsável:
WPRO
ABSTRACT
In 2008, the United States Food and Drug Administration issued guidance which mandated long-term cardiovascular outcome trials (CVOTs) to assess the safety of new antidiabetic drugs for type 2 diabetes. Since 2008, three CVOTs that have studied dipeptidyl peptidase-4 (DPP-4) inhibitors and four CVOTs of a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) have been reported. Each of the completed CVOTs showed the noninferiority of respective drugs to placebo for primary CV composite endpoint. Among them, liraglutide and semaglutide showed a reduction of major adverse cardiovascular events. However, the mechanisms for the observed cardiovascular differences between DPP-4 inhibitors and GLP-1RA, and across individual GLP-1RA are not clearly understood. Therefore, this review will summarize the CVOTs of the DPP-4 inhibitors and GLP-1RA, interpretation of cardioprotective results of incretin-based therapy and the possible mechanism of action.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
United States Food and Drug Administration
/
Diabetes Mellitus Tipo 2
/
Peptídeo 1 Semelhante ao Glucagon
/
Inibidores da Dipeptidil Peptidase IV
/
Incretinas
/
Liraglutida
/
Hipoglicemiantes
Tipo de estudo:
Clinical_trials
/
Guideline
Idioma:
Ko
Revista:
Journal of Lipid and Atherosclerosis
Ano de publicação:
2018
Tipo de documento:
Article